Trial · NCT02919059
Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
NCT02919059, Phase 4, Unknown, IInstituto Gallego de Medicina Vascular
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction. Trials, record NCT02919059. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02919059
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
- NCT number
- NCT02919059
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 159 participants, estimated
- Lead sponsor
- IInstituto Gallego de Medicina Vascular
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin 10 mg, Glimepiride 4 mg
- First posted
- 2016-09-29
- Last updated
- 2017-03-29
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period regarding central systolic blood pressure | 24 weeks | To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding central systolic blood pressure estimated by applanation tonometry |
| Secondary | Effect of dapagliflozin relative to glimepiride at 24 weeks regarding central systolic/diastolic blood pressure | 24 weeks | To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding central systolic/diastolic blood pressure estimated by applanation tonometry. |
| Secondary | Effect of dapagliflozin relative to glimepiride at 24 weeks regarding central pulse pressure | 24 weeks | To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding central pulse pressure estimated by applanation tonometry. |
| Secondary | Effect of dapagliflozin relative to glimepiride at 24 weeks of treatment with inadequate glycemic control regarding 24 hours ambulatory systolic/diastolic blood pressure | 24 weeks | To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding 24 hours ambulatory systolic/diastolic blood pressure. |
| Secondary | Type and number of Adverse events in patienteSafety and tolerability of dapagliflozin relative to glimepiride. | 28 weeks | Type and number of Adverse events to assess the safety and tolerability of dapagliflozin relative to glimepiride. |
| Secondary | Effect of dapagliflozin relative to glimepiride at 24 weeks with inadequate glycemic control regarding augmentation pressure | 24 weeks | To assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding augmentation pressure estimated by applanation tonometry. |
| Secondary | Effect of dapagliflozin relative to glimepiride at 24 weeks with inadequate glycemic control regarding augmentation index | 24 weeks | o assess the effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period in subjects with T2DM, with inadequate glycemic control regarding augmentation index estimated by applanation tonometry. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02919059
GET https://conductscience.org/api/trials/v1/NCT02919059/registered